UNCORRECTED PROOF found in parts of PDSS considering quality of sleep, night-time motor symptoms and daytime sleepiness. In conclusion, we found that DBS, beside motor symptoms, improves sleep problems. doi:10.1016/j.jns.2015.08.1017 971 WFN15-1536 Movement Disorders Pain assessment in wearing off period of levodopa treatment for Parkinson’s disease M. Young-Blood, C. Medyk, J. Sabatini, M. Ferro, C.H. Camargo. Department of Medicine, State University of Ponta Grossa, Ponta Grossa, Brazil Background: Pain is a frequent feature reported in Parkinson’s disease (PD). It can be an early symptom of the disease occurring before the motor symptoms. However, there still is little information about the pain during the wearing off (WO) period of levodopa treatment. Objective: The aim of this study was to assess the pain in the WO period. Methods: A total of 17 patients with diagnosis of idiopathic PD were assessed using the Wearing Off Questionnaire (WOQ-19). The UPDRS-III was applied at three different moments, 3 and 4 hours after levodopa administration and 1 hour after next administration of the drug to confirm the fluctuation o fmotor symptoms. There were included patients with pain at least three months before recruitment. Results: A total of 12 (70.6%) patients had pain. 14 patients (82.4%) demonstrated WO symptoms, 6 had motor symptoms, 2 had nom-motor symptoms and 6 had motor and non-motor symptoms. In 8 patients (57.1%) with nom-motor symptoms pain was referred in 6. There was relief of pain after the next dose of levodopa in 5 of them. There was no difference between presence of pain in the groups with and without WO (p = 1). The pain during WO was not influenced by the presence of motor symptoms (p = 1). There were no difference between the groups with and without pain during WO when compared to levodopa therapy (p = 0.5), years of disease (p = 0.56), Hoehn and Yahr stage (p = 0.43) and the UPDRS-III score (p = 0.77). Conclusion: Pain was a common feature in PD. The pain in the WO had improvement with the levodopa and did not have correlation with staging of PD. It may have different characteristics than other types of pain in PD. doi:10.1016/j.jns.2015.08.1018 972 WFN15-0510 Movement Disorders The spectrum of Neuropsychiatric Symptoms (NPS) in Patients with Parkinson’s Disease (Pwpd) M. Nikitina a , I. Zhukova a , V. Alifirova a , N. Zhukova a , M. Zhestikova b , M. Titova a , E. Koroleva a , J. Mironova a , E. Terskikh a , O. Izhboldina a . a Department of neurology and neurosurgery, Siberian state medical university, Tomsk, Russia; b Department of neurology, Novokuznetsk State Postgraduate Institute, Novokuznetsk, Russia Objective: to investigate spectrum of NPS in PwPD according to the Hoehn&Yahr(H&Y) stage. Background: NPS are common in PD with important consequences for life quality, daily functioning. Patients and methods: 736 PwPD were registered in electronic movement disorders database of the Siberian region. We selected 119 PwPD with equivalent mean daily medications dose, without dementia. Patients were divided into four homogeneous groups: I–28(H&Y 2.0 stage), II–32(H&Y 2.5), III–33(H&Y 3.0), IV–28(H&Y 4.0). 34 healthy control subjects(HCs) were recruited. Clinical assessments were studied by UPDRS(III), MoCA-test, HADS, Beck depression inventory, Epworth Sleepiness Scale, Apathy Scale, Questionnaire for Impulsive-Compulsive Behavior(ICB)– QUIP-RS, SF-36. Results: Significant differences of NPS’ prevalence were in PwPD of I, II, III, IV and control groups. In IV depression was observed most often(76.92% including:46.15%–severe, 30.77%–mild), followed by delusion(30.77%), hallucination(19.23%), anxiety(61.54%:30.77%, 30.77%), apathy(69.23%), the sleep disorders(96.15%:19.23%,76.92%), cognitive impairment(84.6%) and ICB(30.7%); in III depression (66.66%:21.21%,45.45%), anxiety(60.6%:27.27%,33.33%), apathy (63.63%), sleep disorders(90.91%:24.24%,66.67%), cognitive impair- ment(75.75%), ICB(24.0%); in II depression(59.37%:43.75%,15.62%), anxiety(50.25%:31.25%,18.75%), apathy(53.125%), sleep disorders (81.26%:34.38%,46.88%), cognitive impairment(65.6%), ICB(19.0%). Depression(25.0%:43.75%,15.62%), anxiety(32.14%:14.28,17.86%), ap- athy(35.71%), DDS(10.7%) were also commonly observed in I, but delusion, hallucination, euphoria, aberrant motor behavior were seldom presented in I, II(less than 4%). Prevalence of NPS in I-II was similar to HCs than other groups. Conclusions: The spectrum of NPS in PD was most prominent in patients in advanced disease (p b 0.05). Depression was most common NPS in PD. The presence of delusion, hallucination, or aberrant motor behavior could differentiate 2.5 stage from 3.0 stage, from 4.0 stage. The NPS were not prevalent in PD with 2.0 stage. doi:10.1016/j.jns.2015.08.1019 973 WFN15-0429 Movement Disorders Influence of non-motor symptoms on quality of life in parkinson’s disease patients with different stages by the Hoehn&Yahr scale I. Zhukova a , M. Nikitina a , V. Alifirova a , N. Zhukova a , O. Izhboldina a , M. Titova a , E. Koroleva a , E. Terskikh a , M. Zhestikova b , O. Gileva c . a Department of neurology and neurosurgery, Siberian state medical university, Tomsk, Russia; b Department of neurology, Novokuznetsk State Postgraduate Institute, Novokuznetsk, Russia; c Department of Neurology Neurosurgery and Medical Genetics, Medical Academy, Kemerovo, Russia Background: The implications of non-motor symptoms (NMS) in quality of life (QoL) intensively studied last years. Objective: to find out which of the NMS are better correlated with a low QoL in Parkinson’s disease patients (PwPD) taking into consideration the Hoehn&Yahr (H&Y) Stage. Methods: the study includes 169 PwPD without dementia (MOCA N 18); mean age: 68.8 ± 8.2; mean PD duration: 6.8 ± 4.6; women:men = 93:76; H&Y stages 1–4. Clinical assessments were studied using the UPDRS (III part), HADS, Beck depression inventory, Epworth Sleepiness Scale, Apathy Scale, Questionnaire for Impulsive-Compulsive Disorders (ICD), PDQ-39. Odors’ identification studied using Sniffing Stix Test. Four groups of H&Y Stage were studied(homogeneous by gender, age): I– 12 PwPD (UPDRS 19.5 ± 8.6), II– 56 (UPDRS 28.5 ± 16.4), III– 72 (UPDRS 35.9 ± 18.9), IV– 29 (UPDRS 52.2 ± 33.6). Results: the I group has a high correlation (Spearman coefficient q N 0,5) between PDQ-39 and such NMS as anxiety, depression, cardiovascular disorders, constipation, RLS and paraesthesia. The II Abstracts / Journal of the Neurological Sciences 357 (2015) e255–e294 e293